143 articles
JYB1904 (RPT904)
JYB1904 (RPT904, ozureprubart) is a half-life extended anti-IgE humanized monoclonal antibody developed by China's Jemincare and licensed to RAPT Therapeutics in December 2024 for food allergy, CSU, and asthma development outside Greater China.
Latozinemab
Latozinemab (AL001) is Alector's human IgG1 anti-sortilin antibody meant to raise progranulin in FTD-GRN. It elevated PGRN 165% in the phase 3 INFRONT-3 trial but failed its clinical endpoint; development was discontinued in 2025.
LBL-051
LBL-051: first-in-class CD19×BCMA×CD3 trispecific T-cell engager from Nanjing Leads Biolabs' LeadsBody platform, licensed to Aditum Bio spinout Oblenio Bio for autoimmune B-cell depletion; Phase 1a dosing in Europe since August 2026.
Lebrikizumab
Lebrikizumab (Ebglyss, lebrikizumab-lbkz) is an IgG4 monoclonal antibody interleukin-13 antagonist approved in 2024 for moderate-to-severe atopic dermatitis in patients 12 and older weighing at least 40 kg, dosed 250 mg every 2 weeks after loading.
Lenercept
Lenercept (Ro 45-2081, Tenefuse) was a Roche recombinant p55 TNF receptor-IgG1 Fc fusion protein tested in rheumatoid arthritis, multiple sclerosis, and sepsis; development was discontinued after transient RA efficacy and a failed MS trial.
Lenzilumab
Lenzilumab (KB003) is a humanized IgG1κ monoclonal antibody neutralizing GM-CSF, trialed in rheumatoid arthritis, asthma, CMML, CAR-T CRS, and COVID-19 (LIVE-AIR phase 3); EUA rejected, not approved.
Lerdelimumab
Lerdelimumab (CAT-152, Trabio) is a human IgG4 monoclonal antibody neutralizing TGF-β2, developed by Cambridge Antibody Technology and Genzyme to prevent scarring after trabeculectomy; phase III trials showed no benefit over placebo and development was discontinued.
Litifilimab
Litifilimab (BIIB059) is Biogen's humanized anti-BDCA2 monoclonal antibody for lupus; it suppresses type I interferon from plasmacytoid dendritic cells and showed phase 2 efficacy in cutaneous and systemic lupus, with phase 3 trials ongoing.
Lumasiran
Lumasiran (Oxlumo) is Alnylam's GalNAc-conjugated siRNA silencing HAO1 (glycolate oxidase) to cut oxalate in primary hyperoxaluria type 1; FDA-approved November 2020, EU November 2020, all ages, ILLUMINATE trials.
Lutikizumab
Lutikizumab (ABT-981), AbbVie's dual-variable domain antibody neutralizing IL-1α and IL-1β; failed osteoarthritis phase 2 trials but positive phase 2 hidradenitis suppurativa results, now in phase 3.
Manfidokimab
Manfidokimab (AK120) is Akeso's anti-IL-4Rα monoclonal antibody for moderate-to-severe atopic dermatitis; its Phase III met endpoints in August 2025 and its NMPA NDA was accepted in February 2026.
Margetuximab
Margetuximab, sold as Margenza, is an Fc-engineered monoclonal antibody against HER2 developed by MacroGenics, approved in the US in 2020 with chemotherapy for HER2-positive metastatic breast cancer.
Marnetegragene autotemcel
Marnetegragene autotemcel (KRESLADI, marne-cel, formerly RP-L201) is Rocket Pharmaceuticals' autologous lentiviral gene therapy adding ITGB2 copies; FDA accelerated approval March 26, 2026 for pediatric severe LAD-I.
Mepolizumab
Mepolizumab (Nucala) is GlaxoSmithKline's humanized anti-IL-5 IgG1 kappa monoclonal antibody, first FDA-approved November 2015 for severe eosinophilic asthma; 100 mg subcutaneously every 4 weeks, halving exacerbations, with later indications in CRSwNP, COPD, EGPA, and HES.
Mirikizumab
Mirikizumab (Omvoh, mirikizumab-mrkz), Eli Lilly's humanized IgG4 antibody against IL-23 p19, treats moderate-to-severe ulcerative colitis and Crohn's disease; first approved in Japan in March 2023 and by the FDA in October 2023.
Misitatug blivedotin
Misitatug blivedotin (RC88) is RemeGen's mesothelin-targeting antibody-drug conjugate, a humanized anti-MSLN IgG1 linked to MMAE via a cleavable linker, in phase 1/2 trials for ovarian, lung, and cervical cancers.
Mosunetuzumab
Mosunetuzumab (Lunsumio, Lunsumio Velo) is a humanized CD20 x CD3 bispecific T-cell engager antibody approved for relapsed/refractory follicular lymphoma after two or more systemic therapies, delivering 80% response rates via T-cell redirection.
MTX-13 (DAY301)
MTX-13, also called DAY301 or CB-002, is a PTK7-targeting antibody-drug conjugate (Ab13 plus T1000 linker carrying eight exatecan molecules) developed by Multitude Therapeutics and licensed to Day One Biopharmaceuticals in 2024; it is in Phase 1 testing for solid tumors.
Muromonab-cd3
Muromonab-CD3 (OKT3, Orthoclone OKT3) is a murine IgG2a anti-CD3 monoclonal antibody, the first FDA-approved therapeutic mAb (1986), used for acute transplant rejection and withdrawn in 2010.
Natalizumab
Natalizumab (Tysabri; biosimilar Tyruko, natalizumab-sztn) is a humanized anti-α4-integrin IgG4κ monoclonal antibody given 300 mg IV every four weeks for relapsing MS and Crohn's disease, withdrawn 2005 and reintroduced 2006 over PML risk.
Nemolizumab
Nemolizumab (Nemluvio, nemolizumab-ilto, code CIM331) is a humanized anti-IL-31 receptor alpha monoclonal antibody approved by FDA (2024) and EMA (2025) for prurigo nodularis and later atopic dermatitis, dosed subcutaneously every 4 weeks.
Nerelimomab
Nerelimomab (CDP571, Humicade, BAY 103356) is a humanized anti-TNF-alpha IgG4 monoclonal antibody developed by Celltech; it showed modest short-term benefit in Crohn's disease but failed steroid-sparing and maintenance endpoints and was never approved.
Nomacopan
Nomacopan, formerly known as Coversin, is an investigational small protein derived from soft tick saliva that inhibits complement C5 and leukotriene B4, developed by Akari Therapeutics for rare inflammatory diseases.
Obexelimab
Obexelimab is a monoclonal antibody targeting CD19 and FcγRIIB that inhibits B-cell signaling without depleting B cells, developed for autoimmune diseases including IgG4-related disease.
Ociperlimab
Ociperlimab (BGB-A1217), BeiGene's humanized IgG1 anti-TIGIT checkpoint antibody with Fc-competent ADCC activity, tested with tislelizumab in AdvanTIG trials; phase 3 AdvanTIG-302 in NSCLC stopped for futility and lung cancer development was discontinued.
Ocrelizumab
Ocrelizumab (Ocrevus, Ocrevus Zunovo) is a CD20-directed monoclonal antibody depleting B cells, FDA-approved March 2017 for relapsing and primary progressive multiple sclerosis, dosed 600 mg IV every 24 weeks.
Odronextamab
Odronextamab (REGN1979, Ordspono) is Regeneron's fully human IgG4 CD20 x CD3 bispecific antibody for relapsed/refractory follicular lymphoma and DLBCL; EU conditional approval August 2024, FDA complete response letters.
Ofranergene obadenovec
Ofranergene obadenovec (ofra-vec, VB-111) is a non-replicating adenovirus 5 gene therapy from VBL Therapeutics targeting tumor blood vessels; its phase III OVAL ovarian cancer trial missed survival endpoints.
Olokizumab
Olokizumab (OKZ, CDP6038), a humanized anti-IL-6 monoclonal antibody blocking the gp130 Site 3 epitope, developed by UCB Pharma and R-Pharm, approved in Russia for rheumatoid arthritis.
Olvimulogene nanivacirepvec
Olvimulogene nanivacirepvec (Olvi-Vec, GL-ONC1, GLV-1h68) is Genelux's investigational oncolytic vaccinia virus (LIVP strain) with reporter-gene insertions, tested in over 150 patients; lead program is phase 3 ovarian cancer (OnPrime/GOG-3076) plus phase 2 NSCLC.